[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523169":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":37,"locations":42,"responsibleParty":59,"collaborators":61,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":10,"studyType":94,"phases":10,"briefSummary":95,"conditions":96,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Alzheimer's Disease (AD)",null,"The study will collect PET\u002FMR multimodal imaging data, including brain structure, cerebral perfusion, brain function, glucose metabolism, and Aβ deposition, from 100 healthy volunteers, 250 patients with MCI, and 300 patients with AD. Abnormal changes in imaging biomarkers will be analyzed quantitatively, specifically for AD, to determine the specific quantitative threshold for diagnosing AD using 18F-FDG PET and 18F-AV-45 PET and establish imaging biomarkers for early diagnosis of AD. Longitudinal follow-up will be conducted to analyze multimodal imaging data dynamically and discover imaging biomarkers for early prediction of subjective cognitive decline (SCD), MCI, and AD progression.",[13],"Device: PET\u002FMR",{"label":15,"type":10,"description":16,"interventionNames":17},"Parkinson's Disease (PD)","The study aims to collect PET\u002FMR multimodal imaging data from 250 patients with rapid eye movement sleep behavior disorder (RBD) and 300 patients with Parkinson's disease (PD) across multiple centers. The imaging data will include brain structure, brain iron deposition, brain function, glucose metabolism, and vesicular monoamine transporter levels, among other imaging biomarkers. Abnormal changes in these imaging biomarkers will be analyzed quantitatively to determine the specific quantitative threshold for diagnosing PD using 18F-FDG PET and 18F-AV-133 PET and establish imaging biomarkers for early diagnosis of PD. Longitudinal follow-up will be conducted to dynamically analyze the multimodal imaging data and discover imaging biomarkers for early prediction of RBD and PD progression.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Epilepsy(EP)","The study aims to collect PET\u002FMR multimodal imaging data from 550 patients with epilepsy across multiple centers. The imaging data will include brain structure, brain function, glucose metabolism, and microglial cell activity, among other imaging biomarkers, to identify abnormal changes characteristic of epilepsy. Key features will be quantitatively analyzed to determine the specific quantitative threshold for diagnosing epilepsy using 18F-FDG PET and 18F-DPA714 PET and establish imaging biomarkers for epilepsy diagnosis. Using pathological results as the gold standard, the analysis of imaging data from lesions and surrounding brain tissue aims to discover imaging biomarkers that differentiate lesions from normal brain tissue and establish imaging markers for precise localization of epilepsy lesions.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Malignant Brain Tumors(MBT)","A total of 550 patients with malignant brain tumors (gliomas, metastatic tumors, and lymphomas) were collected from multiple centers for PET\u002FMR multimodal imaging of brain structure, brain function, glucose metabolism, and amino acid metabolism, analyzing the characteristic abnormal changes in imaging markers. Using pathological results as the gold standard, specific quantitative threshold values for diagnosing different pathological types of malignant brain tumors using 18F-FDG PET and 18F-FET PET were determined, establishing imaging biomarkers for the diagnosis of malignant brain tumor pathology. Analysis of imaging data of the tumor and surrounding brain tissue revealed imaging markers for distinguishing tumors from surrounding normal brain tissue, enabling precise localization of malignant brain tumors.",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"DEVICE","PET\u002FMR","PET\u002FMR device is used for pre-treatment evaluation and efficacy follow-up of four types of diseases",[9,19,23,15],[33],{"name":34,"affiliation":35,"role":36},"Jie Lu, Phd","Xuanwu Hospital of Capital Medical University","PRINCIPAL_INVESTIGATOR",[38],{"name":34,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","+86 13309824318","imaginglu@hotmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Xuanwu hospital","RECRUITING","Beijing","Beijing Municipality","100053","China","CN",{"type":52,"coordinates":53},"Point",[54,55],116.39723,39.9075,{"lat":55,"lon":54},[58],{"name":34,"role":39,"phone":40,"phoneExt":10,"email":10},{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[62,64,66,68,70,72,74,76,78],{"name":63,"class":6},"Peking University Cancer Hospital & Institute",{"name":65,"class":6},"Shanghai Zhongshan Hospital",{"name":67,"class":6},"Wuhan TongJi Hospital",{"name":69,"class":6},"Henan Provincial People's Hospital",{"name":71,"class":6},"Sun Yat-sen University",{"name":73,"class":6},"Shanghai East Hospital of Tongji University",{"name":75,"class":6},"The First Affiliated Hospital with Nanjing Medical University",{"name":77,"class":6},"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences",{"name":79,"class":6},"Shanghai Jiao Tong University School of Medicine","100523169","clinical-applicantion-of-multi-tracer-petmr-imaging-in-neurological-disordersdisease-100523169",false,"NCT06092125","Clinical Applicantion of Multi-Tracer PET\u002FMR Imaging in Neurological Disorders\u002FDisease","CAMIND","Inclusion Criteria:\n\n1. Patients diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD), rapid eye movement sleep behavior disorder (RBD) or Parkinson's disease (PD), epilepsy, malignant brain tumors based on clinical guidelines.\n2. Patients admitted to our hospital for inpatient treatment.\n\nExclusion Criteria:\n\n1. Patients who have undergone non-invasive\u002Fminimally invasive treatments such as radiotherapy or chemotherapy within the past three weeks. And Patients who have taken Alzheimer's disease-related and Parkinson's disease-related treatment drugs within the past month.\n2. Patients with persistent seizures or status epilepticus that cannot be controlled by medication, resulting in an inability to cooperate with the examination.\n3. patients with poorly controlled blood sugar and ineffective medication intervention.\n4. Patients with absolute contraindications for PET\u002FMR examination.\n5. Karnofsky Performance Score (KPS) \\\u003C60.",true,"ALL","18 Years","60 Years",{"count":92,"type":93},2300,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to learn about the application of domestic PET\u002FMR in major brain diseases. The main questions it aims to answer are:\n\n* Overcome the bottleneck of early accurate diagnosis and treatment in major brain diseases clinical practice.\n* Promote the clinical application of domestic PET\u002FMR, enhance international competitiveness. Participants will have a PET\u002FMR scan of the brain.",[97,98,99,100],"Alzheimer Disease","Parkinson Disease","Epilepsy","Malignant Brain Tumor","2025-07-14",{"date":103,"type":104},"2025-07-16","ACTUAL",{"date":106,"type":104},"2022-10-01",{"date":108,"type":93},"2028-10-31",{"name":5,"class":6},1]